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toxicity, no antidiphtheria serum was adminis-
tered. The patient became well and was
discharged on day 4.
In the first case, a throat culture could not be
done because the patient had already received
local antiseptic paint. However, the diagnosis
was clinically consistent with classic diphtheria
with features of toxicity. In the second case,
diphtheria was suspected only after bacteriologic
examination. Unlike patient 1, patient 2 had no
evident features of systemic toxicity. Hence the
isolate could be nontoxigenic. Localized diphthe-
ria due to nontoxigenic C. diphtheriae is known
to occur (1).
The two patients did not give a complete
history of immunization and may not have been
vaccinated (or may have been partially
vaccinated) with DPT. On the Indian subconti-
nent, DPT vaccination coverage is reported to be
80%. However, it may not be so in all areas, and
immunization may have decreased to approxi-
mately 50% in certain areas of Southeast
Asia (2). This may also be true in certain areas of
eastern Nepal. An immunization status survey
done in midwestern Nepal from 1989 to 1990
showed that DPT coverage was unsatisfactory (3).
Lack of sustained immunization may even result
in outbreaks. The recent epidemics of diphtheria
in the Ukraine, Russian Federation, and other
countries of the former Soviet Union are
examples of resurgence due to ineffectively
maintained immunization programs (4,5).
Diphtheria, still occasionally seen in many
Southeast Asian countries including India and
Nepal, is thought to be declining in these areas.
However, accurate data have not been recently
available, particularly from Nepal, because
reporting is infrequent,  laboratory confirmation
is not available, and the extent of carriers is not
clearly known (2).
These two cases show the persistence of
diphtheria in a population in Nepal immunized
with DPT and underscore the need for careful
surveillance, laboratory documentation of clini-
cal diphtheria, and increased immunization of
children in this area.
H. Srinivasa, S.C. Parija, and M.P. Upadhyaya
B.P. Koirala Institute of Health Sciences,
Dharan, Nepal
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Commercial Use of Burkholderia cepacia
To the Editor: In their review of the potential
threat to human health by the commercial use of
Burkholderia cepacia, Holmes et al. (1) focus on
the biopesticidal uses of this bacterium in
agriculture. By virtue of its ability to antagonize
a number of soilborne plant pathogens,
B. cepacia is an attractive natural alternative to
currently used chemical pesticides, such as
captan, mancozeb, and metalaxyl. The replace-
ment of these highly toxic agents, which are
among the mainstays of crop protection
chemicals, by safer products is a laudable goal.
However, despite being nonpathogenic to
healthy humans (and thus classified as a Biosafety
Level 1 species), B. cepacia can cause life-
threatening pulmonary infection in persons with
cystic fibrosis. Holmes et al. call for a moratorium
on the use of B. cepacia in agriculture until more
is known about risks from such use.
Perhaps of greater concern than agricultural
use is B. cepacias use as a bioremedial agent.
Holmes et al. only briefly refer to the capacity of
this species to degrade chlorinated aromatic
substrates such as those found in certain
pesticides and herbicides. By virtue of its
extraordinary metabolic versatility, B. cepacia
can use such compounds as nutrient carbon
energy sources. In addition, some strains
produce enzymes capable of degrading
nonnutritive substrates, such as trichloroethyl-306 Emerging Infectious Diseases Vol. 5, No. 2, MarchApril 1999
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ene (TCE), a major ground water contaminant
used in the dry cleaning industry and in
degreasing solvents.
The degree to which B. cepacia is being used
in bioremediation products is unknown; how-
ever, the species has been used extensively to
degrade ground water TCE contamination in at
least one large U.S. city. A number of
environment-friendly bioremediation products
containing only naturally occurring, nonpatho-
genic bacteria are being marketed for use in
drain opening and grease eradication systems.
Because their formulations are proprietary, it is
not known if these products contain B. cepacia;
however, franchises that distribute such totally
natural, noncorrosive, nontoxic products specifi-
cally target fast-food restaurants, photo process-
ing facilities, and hospital radiology departments.
In the United States, the biopesticidal use of
microorganisms such as B. cepacia is regulated
by the Environmental Protection Agency (EPA)
under the Federal Insecticide, Fungicide, and
Rodenticide Act; however, the use of naturally
occurring, nonpathogenic bacteria as bioremedial
agents is essentially unregulated. Only new
microorganisms (i.e., intergeneric or formed by
combining genetic material from organisms in
different genera) are regulated by EPA under the
Toxic Substances Control Act (TSCA) (2).
Ironically, TSCA regulations provide a strong
disincentive to the development of safer
microbiologic alternatives for use in
bioremediation. For example, although the
genetic elements responsible for TCE degrada-
tion by B. cepacia have been cloned, their
recombination into another nonpathogenic
bacterial host (e.g., Escherichia coli) would
constitute a new microorganism, the licensure of
which would be considered prohibitively time-
consuming and expensive by many companies.
In Canada, biopesticidal uses of microorgan-
isms are regulated by the Pest Management
Regulatory Agency of Health Canada, under the
Pest Control Products Act (PCPA); bioremedial
uses are regulated by Environment Canada
under the Canadian Environmental Protection
Act (CEPA) (3). Both naturally occurring and
genetically engineered microorganisms are
strictly controlled under these acts. However,
accurate species identification is the cornerstone
of all notification of products under the Canadian
regulations. This presents a further dilemma. At
least five genomovars (discrete species) consti-
tute what has recently been designated the
B. cepacia complex (4). Insofar as the taxonomy
of this group is poorly defined, there are no
conventional taxonomic designations to distin-
guish pathogenic from nonpathogenic species. At
present, it appears that all five B. cepacia
genomovars are capable of causing infections in
vulnerable persons (4).
Because the epidemiology of B. cepacia
complex infection in humans is incompletely
understood, the threat posed by the inclusion of
this species in biopesticides and bioremedial
products is difficult to quantify. However, we
agree with Holmes et al. that such use should be
approached with considerable caution. In a
broader context, the commercial use of B. cepacia
illustrates our incomplete understanding of
nonpathogenic bacteria and their potential to
cause human disease. Regulations governing the
use of microorganisms in industry must
constantly adapt to keep pace with the
emergence of infections due to nonpathogens and
limit risk to human health.
John J. LiPuma* and
Eshwar Mahenthiralingam
*MCP Hahnemann University, St Christophers
Hospital for Children, Philadelphia, Pennsylvania,
USA; and University of British Columbia,
Vancouver, British Columbia, Canada
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Human Rabies in Israel
To the Editor: Rabies, a major zoonotic disease in
the Middle East, has two main epidemiologic
forms: urban and sylvatic. The last case of